Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Common Equity (2017 - 2025)

Eton Pharmaceuticals' Common Equity history spans 8 years, with the latest figure at $26.2 million for Q4 2025.

  • On a quarterly basis, Common Equity rose 7.07% to $26.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $26.2 million, a 7.07% increase, with the full-year FY2025 number at $26.2 million, up 7.07% from a year prior.
  • Common Equity hit $26.2 million in Q4 2025 for Eton Pharmaceuticals, up from $23.1 million in the prior quarter.
  • Over the last five years, Common Equity for ETON hit a ceiling of $26.2 million in Q4 2025 and a floor of $11.2 million in Q3 2022.
  • Historically, Common Equity has averaged $17.7 million across 5 years, with a median of $16.4 million in 2023.
  • Biggest five-year swings in Common Equity: soared 1028.24% in 2021 and later tumbled 37.91% in 2022.
  • Tracing ETON's Common Equity over 5 years: stood at $17.6 million in 2021, then decreased by 25.82% to $13.1 million in 2022, then grew by 18.34% to $15.5 million in 2023, then skyrocketed by 57.83% to $24.4 million in 2024, then grew by 7.07% to $26.2 million in 2025.
  • Business Quant data shows Common Equity for ETON at $26.2 million in Q4 2025, $23.1 million in Q3 2025, and $24.0 million in Q2 2025.